Return to Hematology Alert Section
New acute myeloid leukemia research from Soochow University outlined
December 31st, 2007
2007 DEC 31 -- According to a study from Suzhou, People's Republic of China, "Translocations involving 21q22 are commonly observed in both de novo and therapy-related acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). They often result in the disruption of RUNX1 and give rise to fusion genes consisting of RUNX1 and different partner genes, which contribute to leukemogenesis." "To date, at least 21 such translocations are known from the literature. Here we report two novel translocations involving the RUNX1 gene: t(1,21)(q12;q22) in a 53-year-old woman with AML-M5b and t(11;2 1)(q I 3;q22) in a 65-year-old man with AML-M2," wrote H.P. Dai and colleagues, Soochow University. The researchers concluded: "The abnormalities revealed by R-banding karyotypic analysis were confirmed with interphase and metaphase fluorescence in situ hybridization (FISH), chromosome painting, and M-FISH." Dai and colleagues published the results of their research in Cancer Genetics and Cytogenetics (Two novel translocations disrupt the RUNX1 gene in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2007;177(2):120-124). For additional information, contact Y.Q. Xue, Soochow University, First Affiliated Hospital, Jiangsu Institute Hematology, 188 Shizi St., Suzhou 215006, People's Republic of China. The publisher of the journal Cancer Genetics and Cytogenetics can be contacted at: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA. Keywords: People's Republic of China, Suzhou, Acute Myeloid Leukemia, Cancer, Drug Development, Hematology, Myelodysplastic Syndromes, Oncology, Pharmaceuticals, Therapy, Treatment, Soochow University. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
Return to Hematology Alert Section
|
